BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40–50% of cases are positive. To uncover other potential targetable mutations, we performed whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559,...

詳細記述

保存先:
書誌詳細
主要な著者: Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L., Hicks, Donna J., Bozon, Viviana, Glaspy, John A., Rosen, Neal, Solit, David B., Netterville, James L., Vnencak-Jones, Cindy L., Sosman, Jeffrey A., Ribas, Antoni, Zhao, Zhongming, Pao, William
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3449158/
https://ncbi.nlm.nih.gov/pubmed/22798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0097
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料